IGF2BP1 and rectal cancer: Nevertheless, we found that IGF2BP1 expression (probe: 227377_at*) was higher in non-responders to any chemotherapy (5-fluorouracil, oxaliplatin, bevacizumab, irinotecan, and capecitabine) than in responder rectal cancer patients (Figure 3C).